Prestige Consumer Healthcare (PBH) Cash & Current Investments (2010 - 2026)
Prestige Consumer Healthcare (PBH) posted quarterly Cash & Current Investments of $62.4 million for Q4 2025, up 22.6% year-over-year from $50.9 million in Q4 2024, and down 47.63% quarter-over-quarter from $119.1 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Cash & Current Investments (2010 - 2026) Analysis & Trends
Prestige Consumer Healthcare's Cash & Current Investments history runs 16 years deep, the most recent figure standing at $62.4 million for Q4 2025.
- In Q4 2025, Cash & Current Investments rose 22.6% year-over-year to $62.4 million; the TTM figure through Dec 2025 stood at $62.4 million (up 22.6% YoY), while the FY2025 annual figure was $97.9 million, up 110.64% from the prior year.
- Cash & Current Investments for Q4 2025 stood at $62.4 million, down from $119.1 million in the prior quarter.
- The five-year high for Cash & Current Investments was $163.6 million in Q2 2021, with the low at $21.0 million in Q4 2021.
- The 5-year median for Cash & Current Investments is $53.1 million (2023), against an average of $64.5 million.
- Peak annual rise in Cash & Current Investments reached 310.88% in 2022, while the deepest fall reached 78.08% in 2022.
- Prestige Consumer Healthcare's Cash & Current Investments stood at $21.0 million in 2021, then jumped by 310.88% to $86.4 million in 2022, then dropped by 26.34% to $63.6 million in 2023, then declined by 20.03% to $50.9 million in 2024, then gained by 22.6% to $62.4 million in 2025.
- Business Quant data shows PBH's Cash & Current Investments at $62.4 million in Q4 2025, $119.1 million in Q3 2025, and $139.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 164.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.44 Bn | 2.37 Bn | - | 63.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.87 Mn |
| Dec 31, 2025 | 62.37 Mn |
| Sep 30, 2025 | 119.11 Mn |
| Jun 30, 2025 | 139.50 Mn |
| Mar 31, 2025 | 97.88 Mn |
| Dec 31, 2024 | 50.87 Mn |
| Sep 30, 2024 | 51.54 Mn |
| Jun 30, 2024 | 34.26 Mn |
| Mar 31, 2024 | 46.47 Mn |
| Dec 31, 2023 | 63.62 Mn |
| Sep 30, 2023 | 60.07 Mn |
| Jun 30, 2023 | 54.58 Mn |
| Mar 31, 2023 | 58.49 Mn |
| Dec 31, 2022 | 86.36 Mn |
| Sep 30, 2022 | 42.44 Mn |
| Jun 30, 2022 | 35.87 Mn |
| Mar 31, 2022 | 27.19 Mn |
| Dec 31, 2021 | 21.02 Mn |
| Sep 30, 2021 | 42.82 Mn |
| Jun 30, 2021 | 163.62 Mn |